It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Investigational Drug Treatment Study for Patients with Lung Cancer

Clinical Trial Title: 
An open label, dose-finding and proof of concept study of the PD-L1 Probody™ therapeutic, CX-072, as monotherapy and in combination with Yervoy® (ipilimumab) or with Zelboraf® (vemurafenib) in subjects with advanced or recurrent solid tumors or lymphomas
Clinical Trial Protocol ID: 
16080802
Clinical Trial Investigator Name: 
Mary Jo Fidler, MD
Clinical Trial Protocol Description: 

This is the first study in humans for an investigational drug called CX-072. The purpose of this study is to look at the possible side effects, safety and tolerability of CX-072 when given alone or in combination with ipilimumab or vemurafenib and to find the highest tolerated dose of CX-072 taken safely alone or in combination with ipilimumab or vemurafenib. Ipilimumab is approved by the FDA for the treatment of melanoma. Vemurafenib is approved by the FDA for the treatment of melanoma with a specific change in its genes.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have metastatic or advanced unresectable tumors that progressed on standard therapy.
  • Agree to provide mandatory archival tissue or fresh biopsy.

You will be excluded from the study if any of the following criteria apply to you:

  • Have had prior therapy with a chimeric antigen receptor (CAR) T-cell containing regimen.
  • Have a history of severe allergic or anaphylactic reactions to human monoclonal antibody therapy or known hypersensitivity to any Probody therapeutic.
  • Have a history of allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Phone: 
(312) 563-3921
Contact Name: 
Emily Rubenstein, RN